CRN 01941
Alternative Names: CRN-01941Latest Information Update: 02 Oct 2021
At a glance
- Originator Crinetics Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Somatostatin receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuroendocrine tumours
Most Recent Events
- 09 Apr 2020 Discontinued - Phase-I for Neuroendocrine tumours (In volunteers) in Australia (PO) as the compound did not indicate an improvement over paltusotine in early trials
- 09 Apr 2020 Discontinued - Preclinical for Neuroendocrine tumours in USA (PO) as the compound did not indicate an improvement over paltusotine in early trials
- 03 May 2019 Crinetics Pharmaceuticals plans a phase I trial (In healthy volunteers) in Australia in April 2019 , (NCT03936166)